New cell culture plate eliminates edge effect during extended incubation
Thermo Scientific Nunc Edge 2.0 plate is designed to cost effectively increase cell consistency and productivity in cell-based assays.
A new 96-well plate is uniquely engineered to virtually eliminate evaporation during lengthy incubation, enabling full-plate usage and increased well-to-well cell consistency for improved productivity in cell culture assays at a cost comparable to a standard 96-well plate.
The Thermo Scientific Nunc Edge 2.0 96-Well Plate features a surrounding moat that, when filled with sterile water or media, serves as an evaporation barrier during extended incubation. As a result, edge effect and its associated risks of heterogeneous or biased results decrease. Even after long incubation periods of up to four days, the overall plate evaporation rate is reduced to less than two percent. More samples per plate can therefore be analyzed, increasing assay performance with potentially less cost and related product waste. Due to its large evaporation buffer zones, the next generation Nunc Edge 2.0 96-Well Plate is designed to eliminate well-to-well variability for optimal cell consistency across all of its 96 wells.
“When it comes to growing healthy, viable cells in extended microplate cultures, evaporation is a common yet significant challenge that researchers face,” explains Norman Yung, vice president and general manager, labware and specialty plastics at Thermo Fisher Scientific. “To minimize evaporation and mitigate its negative effects, researchers typically avoid using the outer wells of a standard 96-well plate, ultimately sacrificing 37.5% of the plate’s available real estate. With our new Edge 2.0 plate, scientists can reclaim full use of their plate without having to worry about edge effect. Researchers can also plan their experiments more efficiently and benefit from potential cost savings as a result of using and discarding fewer plates per experiment. We are also pleased to offer the new Edge 2.0 plate at a comparable price to a standard 96-well plate, enabling researchers to benefit from this innovation without compromising tight budgets.”
The new 96-well Edge 2.0 plate is available with both cell culture-treated and non-treated surfaces to suit an extensive range of lab applications. Untreated surfaces allow researchers to add the required coatings themselves, while also being hydrophobic and thus appropriate for growth of suspension cultures that can proliferate and grow without attachment. Conversely, the certified culture-treated option is designed to facilitate cell attachment and growth and is ideal for applications with adherent cell cultures.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance